clinical dermatology

February Clinical Considerations for NPs, PasIn our February Clinical Considerations, we take a look at treatment options for a few common skin disorders.
Alternative to skin graftingThere is a growing burden in wound management. Stem cells will be instrumental in the development of skin substitutes. Novel hydrogel promotes skin regeneration in in vivo experiments.
Updated guidelines for diagnosis, treatment of rosaceaA revised and updated set of criteria and treatment recommendations establishes a phenotype approach to diagnosing and classifying rosacea. This approach marks a transition from treating rosacea patients according to subtype. Global representation may identify research needed to determine whether rosacea is a global condition.
Guidelines recommend early peanut introductionExperts weigh in on what to know about the new addendum to the peanut allergy prevention guidelines.
RF microneedling applicationsOne dermatologists describes her success with radiofreqency microneedling to treat acne and acne scarring.
FDA approves corticosteroid-sparing topical option for eczemaThe FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
January Clinical Considerations for NPs, PAsThis month, we take a look at when to use biologics, advances in pediatric Atopic Dermatitis (AD), and how Trump’s presidency might impact dermatology.
Research suggests new approaches to treat AD
Research suggests new approaches to treat ADResearch aimed at understanding the host-microbial interface in atopic dermatitis is ongoing but already providing insights for novel therapeutic strategies.
Burn depth difficult to determine with the naked eyeVisual assessment of a burn injury is insufficient to judge the depth of a burn; hypertrophic scars left by burn injuries are increasingly being treated with lasers with impressive results.
Rosacea treatmentsNewer topical agents for rosacea including ivermectin and brimonidine are effective, and soon could be joined by oxymetazoline cream, experts say. Initial results from phase 2 trials of minocycline foam in rosacea could be available by year's end.